Status:

COMPLETED

Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy

Lead Sponsor:

Cosmo Technologies Ltd

Conditions:

Ulcerative Colitis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Evaluation of the intraepithelial neoplasia detection rate in patients with long standing ulcerative colitis undergoing mucosal staining with oral methylene blue MMX tablets prior to colonoscopy.

Eligibility Criteria

Inclusion

  • endoscopically verified UC signed written informed consent

Exclusion

  • Known or suspected GI obstruction or perforation Liver or renal impairment, malignancy, pregnancy or lactation, suppressed PT.

Key Trial Info

Start Date :

January 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2012

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT01520324

Start Date

January 1 2012

End Date

July 1 2012

Last Update

February 8 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre for Research & Care of Intestinal Diseases

Rozzano, Italy, 20089

Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy | DecenTrialz